Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.

Fong D, Bisson M, Laberge G, McManus S, Grenier G, Faucheux N, Roux S.

Cell Signal. 2013 Apr;25(4):717-28. doi: 10.1016/j.cellsig.2012.12.003. Epub 2013 Jan 8.

PMID:
23313128
2.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

3.

Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.

Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, Nakamura E, Takano M, Sada KE, Makino H.

Regul Pept. 2010 Jun 8;162(1-3):99-108. doi: 10.1016/j.regpep.2010.03.003. Epub 2010 Mar 24.

PMID:
20346376
4.

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P.

Blood. 2004 Oct 1;104(7):2044-50. Epub 2004 Jun 22.

5.

Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis.

Broege A, Pham L, Jensen ED, Emery A, Huang TH, Stemig M, Beppu H, Petryk A, O'Connor M, Mansky K, Gopalakrishnan R.

J Biol Chem. 2013 Dec 27;288(52):37230-40. doi: 10.1074/jbc.M113.496950. Epub 2013 Nov 14.

6.

Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.

Okamoto M, Murai J, Yoshikawa H, Tsumaki N.

J Bone Miner Res. 2006 Jul;21(7):1022-33.

7.

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.

Bone. 1999 Nov;25(5):517-23.

PMID:
10574571
8.

Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts.

Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y.

Bone. 2000 Oct;27(4):479-86.

PMID:
11033442
9.

The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.

Crockett JC, Schütze N, Tosh D, Jatzke S, Duthie A, Jakob F, Rogers MJ.

Endocrinology. 2007 Dec;148(12):5761-8. Epub 2007 Sep 6.

PMID:
17823253
10.

Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity.

Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, Chihara K.

J Bone Miner Res. 1995 Nov;10(11):1681-90.

PMID:
8592944
11.

Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression.

Ghosh-Choudhury N, Singha PK, Woodruff K, St Clair P, Bsoul S, Werner SL, Choudhury GG.

J Biol Chem. 2006 Jul 21;281(29):20160-70. Epub 2006 May 17.

12.

Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.

Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV.

J Biol Chem. 2009 Nov 27;284(48):33662-70. doi: 10.1074/jbc.M109.010785. Epub 2009 Sep 30.

13.

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.

Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.

J Bone Miner Res. 2000 Sep;15(9):1766-75.

14.

Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.

El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S.

Eur J Pharmacol. 2006 Dec 3;551(1-3):27-33. Epub 2006 Sep 16.

PMID:
17049513
15.

WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.

Chen C, Qin Y, Fang JP, Ni XY, Yao J, Wang HY, Ding K.

Acta Pharmacol Sin. 2015 Sep;36(9):1053-64. doi: 10.1038/aps.2015.65. Epub 2015 Aug 24.

16.

PPAR agonists modulate human osteoclast formation and activity in vitro.

Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA.

Bone. 2007 Jan;40(1):149-59. Epub 2006 Sep 28.

PMID:
17010686
17.

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.

Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D.

J Pathol. 2010 May;221(1):77-86. doi: 10.1002/path.2684.

PMID:
20191615
19.

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.

Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.

J Cell Physiol. 2008 Nov;217(2):409-22. doi: 10.1002/jcp.21511.

PMID:
18543257

Supplemental Content

Support Center